Table 2 A glance of new anti-obesity drugs in the pipeline.
Drug | Company | Mechanism of action | Stage |
|---|---|---|---|
Empatic | Orexigen | Bupropion+zonisamide | Phase III |
Pramlintide | Amylin | Leptin analog + amylin analog | Phase III |
Cetilistat | Alizyme/Takeda | Pancreatic lipase inhibitor | Phase III |
Liraglutide | Novo Nordisk | Long-acting GLP-1 analog | Phase III |
Tesofensine | NeuroSearch | NA/DA/5-HT reuptake inhibitor | Phase II |
Velneperit | Shinogi | Neuropeptide Y5 receptor antagonist | Phase II |
Obinepitide | 7TM | PPY3-36 and pancreatic polypeptide analog | Phase II |
LY377604 | Eli Lilly | β-3 adrenergic receptor agonist | Phase II |
ZGN-433 | Zafgen | MetAP2 inhibitor | Phase I |
PF-04971729 | Pfizer | SGLT2 inhibitor | Phase I |
PF-04620110 | Pfizer | DGAT1 inhibitor | Phase I |
GSK 598809 | GSK | D3 receptor antagonist | Phase I |
GSK 1521498 | GSK | μ-opioid receptor antagonist | Phase I |
